Neurite outgrowth inhibitory levels of organophosphates induce tissue transglutaminase activity in differentiating N2a cells: evidence for covalent adduct formation

Abstract

Organophosphate compounds (OPs) induce both acute and delayed neurotoxic effects, the latter of which is believed to involve their interaction with proteins other than acetylcholinesterase. However, few OP-binding proteins have been identified that may have a direct role in OP-induced delayed neurotoxicity. Given their ability to disrupt Ca2+ homeostasis, a key aim of the current work was to investigate the effects of sub-lethal neurite outgrowth inhibitory levels of OPs on the Ca2+-dependent enzyme tissue transglutaminase (TG2). At 1–10 µM, the OPs phenyl saligenin phosphate (PSP) and chlorpyrifos oxon (CPO) had no effect cell viability but induced concentration-dependent decreases in neurite outgrowth in differentiating N2a neuroblastoma cells. The activity of TG2 increased in cell lysates of differentiating cells exposed for 24 h to PSP and chlorpyrifos oxon CPO (10 µM), as determined by biotin-cadaverine incorporation assays. Exposure to both OPs (3 and/or 10 µM) also enhanced in situ incorporation of the membrane permeable substrate biotin-X-cadaverine, as indicated by Western blot analysis of treated cell lysates probed with ExtrAvidin peroxidase and fluorescence microscopy of cell monolayers incubated with FITC-streptavidin. Both OPs (10 µM) stimulated the activity of human and mouse recombinant TG2 and covalent labelling of TG2 with dansylamine-labelled PSP was demonstrated by fluorescence imaging following SDS-PAGE. A number of TG2 substrates were tentatively identified by mass spectrometry, including cytoskeletal proteins, chaperones and proteins involved protein synthesis and gene regulation. We propose that the elevated TG2 activity observed is due to the formation of a novel covalent adduct between TG2 and OPs.

Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors

“…Representative inhibitors of TG2 are summarized in Table 1. Peptidomimetic; irreversible [14,180,192,195,196] ZED1227 Peptidomimetic; irreversible [197] NTU283 (D003) Irreversible [198] Although the application of TG2 inhibitors to mouse models of Huntington's and Parkinson's diseases showed promising results, this was not the case when translated into clinical trial studies [11]. Encouraging results emerged from considering TG2 inhibition for the treatment of multiple sclerosis, particularly interfering with fibronectin assembly in the ECM by using KCC009 [199,200].…”

Pathogenetic Contributions and Therapeutic Implications of Transglutaminase 2 in Neurodegenerative Diseases

“…In addition to its chemical properties, the warhead must be designed to keep its stability in cellular conditions and prevent off-target effects [202,203]. A commonly used irreversible inhibitor, Z-DON (Z006), has been used to demonstrate the modulation of TG2 in neurite outgrowth and neural differentiation when neurons are exposed to organophosphates [204]. Most recently, Z-DON, reduced molecular events, such as mitochondrial membrane potential loss and synaptic failure, caused by Aβ toxic aggregates in a transgenic model of AD [124].…”

Exploring the Role of Transglutaminase in Patients with Glioblastoma: Current Perspectives

“…Z-don has been used to block glioblastoma cell migration in wound-healing assays, 72 and to help demonstrate that when neurons are exposed to organophosphates, they covalently bind to and activate tTG, causing neurotoxic effects. 73 Arguably the most important inhibitor in this class is…”